CRIS Current Research Information System

GIUNCHI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.516
NA - Nord America 2.949
EU - Europa 2.347
AF - Africa 294
SA - Sud America 168
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.907
SG - Singapore 1.139
CN - Cina 1.129
IT - Italia 599
VN - Vietnam 505
DE - Germania 378
GB - Regno Unito 328
SE - Svezia 266
HK - Hong Kong 241
KR - Corea 201
NL - Olanda 158
IN - India 156
BR - Brasile 118
RU - Federazione Russa 106
FI - Finlandia 102
CI - Costa d'Avorio 89
IE - Irlanda 87
FR - Francia 84
TG - Togo 62
CH - Svizzera 54
SC - Seychelles 52
JO - Giordania 39
JP - Giappone 39
ZA - Sudafrica 36
BG - Bulgaria 33
EE - Estonia 31
CA - Canada 30
UA - Ucraina 30
NG - Nigeria 29
AT - Austria 24
AR - Argentina 22
BE - Belgio 20
ID - Indonesia 19
PL - Polonia 18
MX - Messico 9
EG - Egitto 8
IR - Iran 8
PK - Pakistan 8
BD - Bangladesh 6
CL - Cile 6
ES - Italia 6
LT - Lituania 6
MA - Marocco 6
PY - Paraguay 6
TR - Turchia 6
EC - Ecuador 5
KE - Kenya 5
VE - Venezuela 5
IQ - Iraq 4
AU - Australia 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
LB - Libano 3
AZ - Azerbaigian 2
BO - Bolivia 2
DK - Danimarca 2
EU - Europa 2
LU - Lussemburgo 2
MY - Malesia 2
NP - Nepal 2
PT - Portogallo 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
CY - Cipro 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
LI - Liechtenstein 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PE - Perù 1
PG - Papua Nuova Guinea 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TO - Tonga 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.283
Salva come PNG Salva come JPEG
Città #
Singapore 789
Ashburn 471
Hefei 430
Southend 278
Chandler 254
Hong Kong 240
Fairfield 228
Seoul 201
Bologna 165
Beijing 140
Santa Clara 138
Houston 103
Seattle 103
Ho Chi Minh City 101
Wilmington 99
Hanoi 93
Woodbridge 90
Abidjan 89
Ann Arbor 89
Dublin 87
Princeton 82
Boardman 80
Dallas 80
Cambridge 76
Helsinki 69
Dong Ket 66
Los Angeles 65
Lomé 62
Milan 61
Munich 50
Bern 49
New York 41
Bengaluru 40
Amman 39
Tokyo 34
Sofia 33
Bremen 32
Redondo Beach 31
Westminster 30
Abeokuta 29
Berlin 29
Krefeld 29
Nanjing 29
Padova 26
Turin 25
Buffalo 23
Frankfurt am Main 22
Jinan 21
Tongling 21
Brussels 20
Falkenstein 20
Changsha 19
Redmond 17
Saint Petersburg 17
Turku 17
Guangzhou 16
Nuremberg 16
Jakarta 15
Lappeenranta 15
Rome 15
Tianjin 14
Chicago 13
San Diego 13
São Paulo 13
Redwood City 12
Warsaw 12
London 11
Paris 11
Shanghai 11
Shenyang 11
The Dalles 11
Vienna 11
Florence 10
Naples 10
Toronto 10
Amsterdam 9
Hebei 9
Medford 9
Montreal 9
Council Bluffs 8
Hangzhou 8
Hyderabad 8
Stockholm 8
Bad Bellingen 7
Boston 7
Boydton 7
Düsseldorf 7
Forlì 7
Haiphong 7
Jiaxing 7
Xi'an 7
Biên Hòa 6
Bühl 6
Da Nang 6
Dearborn 6
Des Moines 6
Jacksonville 6
Kyiv 6
Olalla 6
Ottawa 6
Totale 6.000
Salva come PNG Salva come JPEG
Nome #
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 233
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 216
Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging 183
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 182
18F-FACBC PET/CT FOR NODAL STAGING IN HIGH RISK PROSTATE CANCER: PRELIMINARY DIAGNOSTIC ACCURACY ANALYSIS 180
Effectiveness of Radiomic ZOT Features in the Automated Discrimination of Oncocytoma from Clear Cell Renal Cancer 179
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 177
Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease 177
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 176
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 172
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 169
The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates 169
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 168
Compa rison of 18F-fluciclovine PET/CT with 11 C-Choline PET/CT for nodal staging in prostate cancer: a prospective study 165
Fibrotic Adhesive Toxic-fat (F.A.T.): the association of fibrotic and adhesive perirenal fat with peri-operative outcomes of robot-assisted par tial nephrectomy (RAPN) 164
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 163
Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge 162
Incremento dell’attività di RM multiparametrica della prostata: esperienza di un centro a elevato volume di attività 160
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 156
Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers. 153
Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection 151
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 150
Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis. 149
Frozen section analysis of unusual small testicular tumor masses: report of 3 cases 148
The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy 148
Beyond multiparametric MRI and towards radiomics to detect prostate cancer: A machine learning model to predict clinically significant lesions 138
The role of MRI in the detection of local recurrence: Added value of multiparametric approach and Signal Intensity/Time Curve analysis 136
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 136
Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer 134
Incidence, etiology, histologic findings, and courses of thoracic inflammatory aortopathies 131
Primary liver sarcomatous carcinoma: report of two cases and review of the literature. 131
POSSIAMO INCLUDERE NELLA SORVEGLIANZA ATTIVA PER NEOPLASIA PROSTATICA, PAZIENTI CON CGS 3+4 IN UN UNICO PRELIEVO BIOPTICO? RISULTATI A MEDIO TERMINE DI UN SINGOLO CENTRO DOPO REVISIONE ISTOLOGICA SISTEMATICA DEI PRELIEVI BIOPTICI E DEI REPERTI OPERATORI 130
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 130
[68Ga]Ga-FAPI-46 PET/CT for Staging Suspected/Confirmed Lung Cancer: Results on the Surgical Cohort Within a Monocentric Prospective Trial 129
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 129
Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance 129
Revised Gleason Grading System Is a Better Predictor of Indolent Prostate Cancer at the Time of Diagnosis: Retrospective Clinical-Pathological Study on Matched Biopsy and Radical Prostatectomy Specimens. 128
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 125
PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists 125
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 124
Beyond multiparametric MRI and towards radiomics to detect prostate cancer: A machine learning model to predict clinically significant lesions 121
Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients 121
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 120
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 119
MULTIPLE RENAL ONCOCYTIC TUMORS: HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND CYTO-GENETICAL COMPARATIVE ANALYSIS 116
Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge 115
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 115
Abstracts from USCAP 2020: Genitourinary Pathology (860-1046) HPV Status and World Health Organization 2016 Classification of Penile Squamous Cell Carcinoma and Penile Intraepithelial Neoplasia: 206 Cases from a Single, Contemporary, Western Cohort of Patients with Emphasis on the “Discordant Cases" 114
Emerging Molecular Technologies in Genitourinary Tumors 111
Perineural invasion and risk of lethal prostate cancer 109
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial 109
Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis 108
The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. 106
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 105
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 103
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 103
Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones 101
Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap? 97
Role of multiparametric magnetic resonance and ultrasound-guided/MR fusion biopsy in patients with low-risk prostate cancer suitable for active surveillance 95
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 89
Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters 89
Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort 86
Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review 85
null 84
Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with 68Ga-PSMA PET/CT Features in Primary Staging 83
The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors 79
SOX2 and PRAME in the "reprogramming" of seminoma cells 77
First case of bilateral, synchronous anaplastic variant of spermatocytic seminoma treated with radical orchifunicolectomy as single approach: Case report and review of the literature 75
null 73
Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples 73
Role of PD-L1 assessment in advanced NSCLC: does it still matter? 65
Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [68Ga]Ga-FAPI PET/CT 61
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 54
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 51
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors 36
The new classification of renal cell carcinoma: what is the clinical issue? 31
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 26
Totale 9.510
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.462
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.462
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021403 0 0 0 0 0 13 40 20 45 26 27 232
2021/2022845 65 18 30 72 60 35 42 70 38 68 219 128
2022/20231.250 90 168 70 131 116 89 50 61 220 47 89 119
2023/2024687 66 65 44 53 42 95 50 61 108 35 33 35
2024/20252.312 133 244 187 137 240 131 177 96 53 224 211 479
2025/20262.804 633 636 479 431 520 105 0 0 0 0 0 0
Totale 9.510